Addiction & Substance Use

The FDA has issued a complete response letter to Orexo for OX124, a high-dose naloxone nasal spray for opioid overdose reversal.

What is new in research on alcohol use disorder?

To expertly utilize polypharmacy, it is imperative that clinicians stay abreast of new literature, check for drug-drug interactions, and be aware of emerging trends in drug use.

Inhalant use disorder is characterized by the intentional inhalation of volatile substances for their psychoactive effects. Learn more about how to help manage this disorder.

An expert discusses this comorbidity, plus the effects of semaglutide and other GLP-1 agonists on this patient population.

The FDA has authorized the marketing of 4 menthol-flavored e-cigarette products in the United States through the premarket tobacco product application pathway.

Cannabis withdrawal syndrome impacts approximately half of those who use it regularly. How can you help patients cease cannabis use?

With cannabis legalization increasing in the United States, so too are the issues surrounding cannabis access, usage, and use disorders. State by state, take a peek at some of the issues and updates surrounding cannabis.

Here are highlights from the week in Psychiatric Times.

We're highlighting issues in addiction in our special Digital Supplement! Learn more here.

The study aims to collect data to optimize the design of the treatment’s upcoming phase 3 clinical trial.

How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.

An analysis presented at the ASCP Annual Meeting explored the safety and tolerability of the treatment for alcohol and tobacco use disorders.

Write to us now for a chance to be featured in our upcoming Special Report on Addiction.

Here are highlights from the week in Psychiatric Times.

Here’s how an integrated psychosocial and pharmacologic approach can enhance SUD treatment.

Here are highlights from the last day of this year’s APA Annual Meeting.

The Psychiatric Times Substance Use Section Editor reflects on the theme of the 2024 Annual Meeting, plus what he is most excited about in psychiatry.

Here are highlights from the third day of this year’s APA Annual Meeting.

This 2024 APA Annual Meeting poster documented the abuse potential of benzodiazepines and tapering challenges.

Here are highlights from the second day of this year’s APA Annual Meeting.

Here are highlights from the first day of this year’s APA Annual Meeting.

Petros Levounis, MD, MA, talks addiction, buprenorphine, his year as president of the APA, and more at the 2024 Annual Meeting.

What are the connections between cannabis use and the onset of psychotic disorders?

Use this protocol, presented at the 2024 APA Annual Meeting, in patients with cannabis use disorder to bolster likelihood of cannabis cessation or reduction in use.

What is the potential impact of social media overuse and mental health crises in young patients?

A look at the theme for the 2024 American Psychiatric Association Annual Meeting.

Which is the best recommendation for the treatment of alcohol use disorder?

How can psychiatric clinicians improve outcomes for this unique patient population?

How can novel technologies help address stigma and improve care for patients with SUDs?